Aclaris Therapeutics Inc (NASDAQ:ACRS) had its Overweight rating reiterated by Cantor Fitzgerald with a $5.00 price target

ME Staff
-
0

Analyst Ratings For Aclaris Therapeutics Inc (NASDAQ:ACRS)

Today, Cantor Fitzgerald reiterated its Overweight rating on Aclaris Therapeutics Inc (NASDAQ:ACRS) with a price target of $5.00.

There are 2 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Aclaris Therapeutics Inc (NASDAQ:ACRS) is Buy with a consensus target price of $17.3333 per share, a potential 1,650.84% upside.

Some recent analyst ratings include

  • 8/9/2019-Aclaris Therapeutics Inc (NASDAQ:ACRS) had its Overweight rating reiterated by Cantor Fitzgerald with a $5.00 price target
  • 6/27/2019-Aclaris Therapeutics Inc (NASDAQ:ACRS) gets downgraded to Market Perform by Svb Leerink
  • 6/27/2019-Aclaris Therapeutics Inc (NASDAQ:ACRS) gets downgraded to Market Perform by Leerink Swann
  • 2/8/2018-Aclaris Therapeutics Inc (NASDAQ:ACRS) has coverage initiated with a Buy ➝ Buy rating and $53.00 price target
  • On 6/27/2019 James E Flynn, Major Shareholder, sold 699,475 with an average share price of $2.69 per share and the total transaction amounting to $1,881,587.75.
  • On 6/25/2019 James E Flynn, Major Shareholder, sold 454,261 with an average share price of $4.59 per share and the total transaction amounting to $2,085,057.99.
  • On 6/21/2019 James E Flynn, Major Shareholder, sold 339,537 with an average share price of $4.62 per share and the total transaction amounting to $1,568,660.94.
  • On 5/10/2019 James E Flynn, Major Shareholder, sold 614,710 with an average share price of $6.13 per share and the total transaction amounting to $3,768,172.30.
  • On 10/22/2018 Anand Mehra, Director, bought 372,093 with an average share price of $10.75 per share and the total transaction amounting to $3,999,999.75.
  • On 10/4/2018 Stephen A Tullman, Director, bought 7,100 with an average share price of $14.00 per share and the total transaction amounting to $99,400.00.
  • On 8/23/2018 Stephen A Tullman, Director, bought 6,600 with an average share price of $15.00 per share and the total transaction amounting to $99,000.00.

About Aclaris Therapeutics Inc (NASDAQ:ACRS)
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream. Read More…

Recent Trading Activity for Aclaris Therapeutics Inc (NASDAQ:ACRS)
Shares of Aclaris Therapeutics Inc closed the previous trading session at 0.99 −0.030 2.94% with 1.06 shares trading hands.